Tag: 97-5-percent

(Reuters) – Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment. The once-daily fixed-dose combination, glecaprevir/pibrentasvir (G/P), was given to HCV patients without cirrhosis and who were new to treatment in three different studies. About…